slide1 l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
In the forefront of the battle against emerging infectious diseases PowerPoint Presentation
Download Presentation
In the forefront of the battle against emerging infectious diseases

Loading in 2 Seconds...

play fullscreen
1 / 15

In the forefront of the battle against emerging infectious diseases - PowerPoint PPT Presentation


  • 96 Views
  • Uploaded on

In the forefront of the battle against emerging infectious diseases. Avraham Shimon Marilus CEO Dorit Arad CSO and Founder . Mission. Be ready to Rapidly detect Prevent the spread Provide better treatment for infectious diseases particularly those that impose world pandemics threat.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'In the forefront of the battle against emerging infectious diseases' - evelia


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1
In the forefront of the battle against emerging infectious diseases

Avraham Shimon Marilus CEO

Dorit Arad CSO and Founder

mission
Mission

Be ready to

  • Rapidly detect
  • Prevent the spread
  • Provide better treatment

for infectious diseases

particularly those that impose world pandemics threat

slide3

MND’s Platform

Novel (Based on viral enzyme detection)

Rapid (only 3 minutes detection)

Detection of live viruses

For pandemic causing viruses to prevent their spread

For existing viruses to provide a better care

slide4

MND diagnostics

  • Founded in2004 as an incubator company
  • Established a collaboration with BMD (Biomedical Diagnostic, France)
  • Recently completed first round of $4.7 million financing from Swiss investors
  • Achieved proof of concept on the detection of enterovirus meningitis in CSF samplesManpower: 10 persons. Situated in Science Park Nes-Ziona.
slide5
Business Development

The BDC Group

Prof Max Herzberg

Prof. Christian Policard

Ms. Nicole Rieunier-Burle

The MND Team

Mr. AvrahamMarilus CEO and Chairman

Dr. Dorit Arad – CSO and founder

Dr. OurielFaktor VP R&D

Prof. Max Herzberg - Director

Development Team

YanivNevoPh.D

Assaf Ezra

OferNusbaumPh.D

GiladWainreb

Clinical Studies

David Greenberg M.D.,

Medical director, Soroka

Hospital, Israel.

Prof. Dana Wolf, Hadassah Hospital, Israel

slide6

Specific

sequence

Detector

peptide

Quenched tag

The Technology:

Specific Enzymatic Based assay

viral enzyme

+

(I)

(III)

(II)

Peptide color

reaction

advantages
Advantages
  • New IP – new niche in the crowded diagnostics arena
  • Detecting virus in their active stage, unlike RT-PCR and immunoassays
  • Rapid detection relative to PCR (minutes relative to hours)
  • proprietary molecules
  • Detection procedure is simple
  • Inexpensive
  • Could be adjusted to hand-held field usage (airports and public places)
business model
Combination of product development, licensing and partnering leverages MND’s IP and knowhow to its fullestBusiness Model

Partner – Avian Flu (poultry)

BMD Multiplex Meningitis

MND

QPT

Technology

MND CMV

MND single test

Meningitis

Partner – emerging pandemic kit

for outbreak control

MND Avian Flu (Humans)

meningitis rapid detection kit
The need for Detection

Each year in the United States 10 million to 15 million illnesses are attributed to Enterovirus

300,000 Lumbar Punctures are performed in the US every year. This number will grow when there will be a fast detection tool to diagnose the disease.

Current Gold Standard

The “gold standard” for Enterovirus detection is Tissue culture which takes 3 days. RT-PCR takes 5-24 hours

Current Development Status

Proof of concept completed in 2007

Pre-clinical studies planned for Q3 2008

Over 100 clinical CSF samples tested successfully

Meningitis Rapid Detection Kit
slide11

Market Opportunities

1. Persistent viruses (Meningitis, Enterovirus, CMV andRhinovirus)

2. Emerging viruses (Avian Flu, SARS).

ip knowhow
Innovative

MND’s intellectual property includes three pending patents on the detection method, compositions of matters for a wide range of viruses including HCV and detection of avian influenza.

Knowhow

Unique molecular design techniques (QCT) enable the creation of effective molecules, specific to each disease agent, for treatment and detection. Experience in the development of rapid testing formats

IP & knowhow

Creating leverage through MND’s novel IP

company goals 2008 2010
Launch Meningitis Rapid Detection Kit to market in 2009.

Advance MND platform and pipeline products for the detection of: Avian Influenza, CMV, HCV and Foot and Mouth disease.

Complete co-development of a Multiplex Detection Kit with BMD (BioMedical Diagnostics, France).

Establish strategic partnerships with leading Pharma.

Company Goals 2008-2010
summary
Summary
  • MND technology has the potential to become a gold standard for Rapid detection, in non-lab conditions, of active infectious viruses such as: ENV, RHV, CMV, HCV, MFV, Inf.
  • MND broad technology can be expanded for development of Cancer markers and Blood coagulations diseases, and enrich the company pipeline.
  • MND relevant market segments - $13.3B (~34%) of the annual $40B IVD market.
  • We expect to launch our first product for meningitis detection in a year in third quarter of 2009.